You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 169 No. 19, October 26, 2009 TABLE OF CONTENTS
  Archives
  •  Online Features
  Commentary
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Contact me when this article is cited
 Related Content
 •Related article
 •Similar articles in this journal
 Topic Collections
 •Evidence-Based Medicine
 •Patient Safety/ Medical Error
 •Quality of Care, Other
 •Adverse Effects
 •Drug Therapy, Other
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

HEALTH CARE REFORM
Going Off-label Without Venturing Off-Course

Evidence and Ethical Off-label Prescribing

Emily A. Largent, BS; Franklin G. Miller, PhD; Steven D. Pearson, MD, MS

Arch Intern Med. 2009;169(19):1745-1747.

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Following US Food and Drug Administration (FDA) approval, clinicians may lawfully prescribe a drug or biologic agent for treatment regimens not specified in the approved labeling or package insert. This is known as off-label use. A recent study1 found that for 160 common drugs in the United States, off-label use accounted for 21% of all prescriptions. Many off-label uses are accepted as standard of care, for example, use of β-blockers for congestive heart failure. Many other off-label uses, however, lack evidence of clinical efficacy.1 In light of growing concerns about appropriateness and cost, off-label use has been identified as 1 aspect of problematic drug prescribing.2-3

Currently, there is little guidance to distinguish clearly between off-label uses that are well-supported by evidence and those that are not. In this article, we address that gap at the level . . . [Full Text of this Article]

SIGNALS FOR SCRUTINY

New Drugs

Novel Off-label Use

Drugs With Known Serious Adverse Effects

High-Cost Drugs

EVIDENCE LEVELS TO GUIDE OFF-LABEL PRESCRIBING


PHYSICIAN RESPONSIBILITIES AND ACTIONS
Supported Off-label Use

Suppositional Off-label Use

Investigational Off-label Use


COMMENT

AUTHOR INFORMATION


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLE

In This Issue of Archives of Internal Medicine
Arch Intern Med. 2009;169(19):1736.
FULL TEXT  






HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2009 American Medical Association. All Rights Reserved.